Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)
Description
Brief Summary
This is a non-interventional, multinational, multi-center post-marketing study, to further
document the safety and efficacy of pasireotide s.c. administered in routine clinical
practice in patients with Cushing's disease. Patients with Cushing's disease and treated with
pasireotide s.c. alone and in combination with other therapies will be monitored. For this
study, each enrolled patient will be followed up for 3 years after enrollment. Patients who
permanently discontinue pasireotide s.c. prior to completing the 3-year observation period
will be followed up for 3 months after the last dose of pasireotide s.c.
Phase
OtherInclusion and Exclusion Criteria
- Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option
- Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry
- Patients with ectopic ACTH-dependent Cushing's syndrome
- Patients with adrenal Cushing's syndrome
- Patients with Pseudo Cushing's syndrome
Sites
Please contact Anush Arakelyan to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI